N-(5-(4,5-二氢-(1H)-吲哚-2-基)-2-羟基-5,6,7,8-四氢萘-1-基)甲烷磺酰胺氢溴酸 | 107756-30-9

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: N-(5-(4,5-二氢-(1H)-吲哚-2-基)-2-羟基-5,6,7,8-四氢萘-1-基)甲烷磺酰胺氢溴酸
• 中文别名: A61603氢溴酸
• 英文名称: A 61603
• 英文别名: (+/-)-N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide hydrobromide；N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulphonamide hydrobromide；A 61603 Hydrobromide；N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide;hydrobromide
• CAS: 107756-30-9
• 化学式: BrH*C₁₄H₁₉N₃O₃S
• 分子量: 390.301
• InChiKey: LRFLWCZMTGTUEP-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于H2O

计算性质

• 辛醇/水分配系数(LogP)：
  1.76
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.2
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• METHYLENE-CYCLOALKYLACETATE DERIVATIVES AND THEIR USE IN TREATMENT OF NEUROTROPIC CONDITIONS
  申请人：Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.

  公开号：US20200239398A1

  公开（公告）日：2020-07-30

  Methylene-cycloalkylacetate compounds and derivatives thereof and their use in methods for treatment of neurotropic conditions.

  亚甲基环烷基醋酸酯化合物及其衍生物以及它们在治疗神经病症方法中的应用。
• Method of Treatment Using Alpha-1-Adrenergic Agonist Compounds
  申请人：Simpson Paul C.

  公开号：US20100113377A1

  公开（公告）日：2010-05-06

  Methods for treating or preventing cardiomyopathy in a subject by administering an al adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided.
• METHOD OF TREATMENT USING ALPHA-1-ADRENERGIC AGONIST COMPOUNDS
  申请人：Simpson Paul C.

  公开号：US20130040904A1

  公开（公告）日：2013-02-14

  Methods for treating or preventing cardiomyopathy in a subject by administering an α1 adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided.
• ALPHA-1-ADRENERGIC RECEPTOR AGONIST THERAPY
  申请人：The Regents of the University of California

  公开号：US20140121257A1

  公开（公告）日：2014-05-01

  Presented herein inter alia are novel methods of treating heart and brain diseases.
• A SCREENING METHOD, A KIT, A METHOD OF TREATMENT AND A COMPOUND FOR USE IN A METHOD OF TREATMENT
  申请人：ATROGI AB

  公开号：US20160003803A1

  公开（公告）日：2016-01-07

  A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.